Quick Answer
AEON Biopharma, Inc. reported Net Income Loss of -$39.22 million for the year ending 2025.
- AEON Biopharma, Inc. showed a decrease of -193.4% in Net Income Loss from 2024 to 2025.
- This data is from AEON Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2020 to 2025), AEON Biopharma, Inc.'s Net Income Loss has declined by 1,093,043.8%.
- Historical annual values: Fiscal year 2025: -$39.22 million | Fiscal year 2024: $42.01 million | Fiscal year 2022: -$52.56 million | Fiscal year 2021: $8.20 million | Fiscal year 2020: -$3.6 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: